Drug application
RETAVASE (RETEPLASE)
Drugs@FDA BLA 103786 · EKR THERAP
Key facts
| Drug name | RETAVASE |
|---|---|
| Active ingredients | RETEPLASE |
| Application type | BLA |
| Application number | 103786 |
| Company | EKR THERAP |
| Dosage forms | VIAL |
| Strength | 18.8MG/VIAL |
| Marketing status | Prescription |
| Reference listed drug | No |
| Latest submission class | Type 1 - New Molecular Entity |
| Latest submission status date | May 6, 1998 |
At a glance
- 1–9 Submissions
- None Label versions
- 1–9 Products
- None Therapeutic equivalents
- Yes FDA letters on file
- Yes FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: